Auto Injectors Market - Forecast(2025 - 2031)

Overview

The Auto Injectors Market size is forecast to reach USD 177.13 Billion by 2030, after growing at a CAGR of 15.04% during the forecast period 2024-2030. The rising incidence of chronic conditions such as diabetes, multiple sclerosis, rheumatoid arthritis, and psoriasis, as well as life-threatening allergies (e.g., anaphylaxis), is a major driver for the demand for auto-injectors. These conditions often require regular or emergency injections, making self-injection devices a preferred solution for patients. As the global burden of these diseases increases, the need for convenient, accurate, and easy-to-use drug delivery systems like auto-injectors continues to rise. Advancements in the design and functionality of auto-injectors are another key driver. Innovations such as reusable auto-injectors with multiple doses, needle-free injection systems, and smart auto-injectors are enhancing the usability and appeal of these devices. These improvements make auto-injectors even more convenient and user-friendly, particularly for patients who need regular injections or are dealing with emergencies.

Report Coverage

The report “Auto-Injectors Market – Forecast (2024-2030)”, by IndustryARC, covers an in-depth analysis of the following segments of the Auto-Injectors market.

By Type: Disposable Auto-Injectors, Reusable Auto-Injectors

By Indication: Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Others

By End User: Homecare Settings, Hospitals & Clinics, Ambulatory Surgical Centers

By Geography:  North America, South America, Europe, APAC, and RoW

Key Takeaways

•    The North American region is anticipated to dominate the Auto-Injectors market with a value share of approximately 36% in 2023, followed by Europe with a 30% value share in the auto-injectors market.
•    The continued support and funding from the Biomedical Advanced Research and Development Authority (BARDA) for the development and procurement of auto-injectors is a key driver for the North American auto-injector market.

By Type - Segment Analysis

The Disposable Auto-Injectors segment dominated the auto-injectors market in 2023. The increasing incidence of chronic conditions, such as diabetes, rheumatoid arthritis, and allergies, necessitates the need for self-administered medications, which auto-injectors facilitate. Disposable auto-injectors are designed for user-friendliness, allowing patients to administer medications quickly and easily without needing professional assistance. This convenience is appealing to both patients and healthcare providers. For instance, in September 2021, Owen Mumford Pharmaceutical Services launched the Aidaptus® auto-injector platform, a versatile disposable, spring-powered device designed to accommodate both 1 mL and 2.25 mL prefilled glass syringes. This innovative platform features stopper sensing technology and a self-adjusting plunger, allowing for seamless adaptation to different fill volumes without the need for changing parts. Available with two spring strengths to handle various drug viscosities, Aidaptus addresses the growing demand for efficient, user-friendly delivery systems.  

By Indication - Segment Analysis

The Diabetes segment dominated the auto-injectors market in 2023. The global rise in diabetes, particularly type 1 and type 2 diabetes, is a primary driver of the auto-injector market. As more individuals are diagnosed with diabetes, the demand for effective management tools, including auto-injectors for insulin delivery, continues to grow. Auto-injectors offer a user-friendly solution for insulin administration, enabling patients to inject themselves easily and discreetly. This convenience is particularly important for those who require multiple daily injections, as it simplifies the management of their condition and improves adherence to treatment regimens. For instance, the IDF Diabetes Atlas 2021 highlights a significant global diabetes burden, with 10.5% of adults (20-79 years) currently affected, and nearly half unaware they have the condition. By 2045, projections indicate that 1 in 8 adults, around 783 million people, will have diabetes, marking a 46% increase. This escalating prevalence is driving growth in the auto-injector market, as people with diabetes increasingly require self-administered treatments for insulin and other diabetes-related therapies.

By End User - Segment Analysis

The Homecare Settings dominated the auto-injectors market in 2023. Many patients prefer to manage their treatments at home due to the comfort, convenience, and reduced need for frequent hospital or clinic visits. Auto-injectors allow patients to administer their medications, empowering them to take control of their health while avoiding the time, expense, and inconvenience of medical appointments. For instance, in November 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka) launched a new auto-injector version of AJOVY Subcutaneous Injection 225mg (fremanezumab) in Japan, specifically designed for home care settings. With physician approval, this self-injection option allows patients to administer their medication at home every four weeks. This advancement aims to minimize hospital visits and make long-term treatment more convenient and accessible within the comfort of home. The auto-injector market is growing in homecare settings due to a combination of technological advancements, patient preferences, chronic disease management needs, and the drive for cost-effective and convenient healthcare solutions. This trend is expected to continue as the healthcare landscape evolves and patients seek more autonomy in managing their treatments from home.

By Geography - Segment Analysis

North America region dominated the auto-injectors market in 2023.  The USA auto-injector market has emerged as a critical segment within the healthcare landscape, driven by the increasing prevalence of chronic diseases and allergies and advancements in drug delivery technologies. The market is characterized by robust growth, with a rising number of patients seeking self-administration options for conditions such as anaphylaxis, diabetes, and autoimmune diseases. Approximately 33.1 million Americans suffer from food allergies, according to Food Allergy Research and Education. This includes one in thirteen, or 5.99 million, children under 18. The FDA has to accept new products faster since anaphylaxis and other allergies are more common in the United States. As more people suffer from inflammatory and chronic illnesses, there is a greater demand for self-administered medications. Favorable regulations and approval processes for new devices are anticipated to encourage innovation and the entry of new players into the market.

Drivers – Auto-Injectors Market

•    Increased Prevalence of Chronic Conditions 

The increased prevalence of chronic conditions such as diabetes, multiple sclerosis, and rheumatoid arthritis is driving the demand for auto-injectors. According to the Centers for Disease Control and Prevention, the United States had 129 million people with at least one major chronic disease by February 2024, with five of the top ten leading causes of death being avoidable and treatable. Over the last two decades, prevalence has risen, with 42.0% having several illnesses. Chronic diseases have a huge impact on the US healthcare system, accounting for 90.0% of the $4.1 trillion spent yearly. According to the International Diabetes Federation Report in December 2021, diabetes affected approximately 537 million adults aged 20 to 79. By 2030, the total number of people with diabetes is expected to reach 643 million; by 2045, it will reach 783 million. Three out of every four adults with diabetes live in a low- or middle-income country. As these diseases often require long-term, frequent treatments, there is a growing demand for convenient and reliable self-administration methods, which is projected to accelerate the expansion of the auto-injector market.

•    Growing Demand for Biologic Drugs

One of the primary drivers of the auto-injector market is the development of biologics, such as vaccines, antibody-drug conjugates, and monoclonal antibodies, which are frequently not able to be administered orally due to their complex molecules and exacting administration criteria. When compared to oral drugs, injectable therapies frequently offer a faster onset of action and higher bioavailability.  For instance, with a sharp rise in FDA approvals, 2024 has already shown to be a pivotal year for the biologics industry. The FDA approved 9 novel biologics in the first quarter alone, which is a significant increase from the 5 that were approved in the same period in 2023. This increase in approvals ushers in a new age in healthcare, highlighting the quick advancements and increased attention being paid to biologics in medical therapy. The growing use of biologic drugs, especially for the treatment of autoimmune diseases like psoriasis, and Crohn’s disease is expected to increase demand for devices that can efficiently administer these therapies.

•    Rising Awareness of Anaphylaxis

The increasing incidence of food allergies and anaphylaxis is driving growth in the global auto-injector market. Food allergies can result in anaphylaxis, a severe and quick allergic reaction. Breathing difficulties, edema, hives, and a decrease in blood pressure are some of its symptoms. For example, statistics released in April 2024 by the Asthma and Allergy Foundation of America show that more than 100 million Americans experience allergies each year, including eczema, food allergies, and seasonal allergies. More than one in four American children and nearly one in three American adults suffer from a food allergy, eczema, or seasonal allergies. In the United States, food allergy-related anaphylaxis is thought to cause 90,000 ER visits annually. Autoinjectors are becoming available to people at risk and their caregivers because of awareness campaigns and educational initiatives that are disseminating knowledge about anaphylactic symptoms and the significance of intervention. The increased focus on these concerns has resulted in a surge in the demand for autoinjectors.

Challenges – Auto-Injectors Market

•    Regulatory Challenges

The overall market's expansion is projected to be impeded by the industry's stringent regulatory environment for auto-injector approval. Auto-injectors are regulated as combination products by health authorities such as the U.S. FDA and the European Medicines Agency (EMA). This means they must meet both medical device and drug product requirements. Depending on the region, the regulatory body handles the approval of the device and the drug separately, which complicates the approval process and requires alignment between multiple regulatory agencies. This suggests there may be confusion among marketing application holders due to inconsistent recognition of the device components of combination drugs. These overlapping regulatory frameworks often create challenges in ensuring that both the device and the drug are compliant before they can be marketed.

•    Handling Multiple Drug Viscosities

OEMs face the most challenging hurdle in developing single-design auto-injectors for an assortment of drugs and biologics with variable viscosities. Springs of varying physical properties, such as structure, length, and thickness, are required to provide a spring rate sufficient to drive higher-viscosity medicines and biologics through the prefilled syringe to the hypodermic needle. For example, low viscosity can cause early delivery and should be avoided with lesser spring forces, whereas high viscosity can prevent premature delivery and necessitate bigger spring forces and increase injection time. According to the research by Oval Medical Technologies in 2021, high-viscosity formulations are being developed at an increasing rate - consequently, the technology being developed to assist their administration must match their complex needs. Many pharmaceutical companies currently lack the expertise required to build auto-injectors capable of delivering various medicines and biologics of varying viscosities, which is predicted to impede auto-injector industry growth.

Market Landscape

Partnerships, Product Launches, and Expansions are key strategies adopted by players in the auto-injectors market. In 2023, The Auto-InjectorsMarket share has been consolidated by the top fifteen players accounting for 71.55% of the share. Major players in the auto-injectors market are AbbVie, Inc., Sanofi, Novartis, Teva Pharmaceutical, Amgen, Eli Lilly and Company, Biogen Idec, Becton, Dickinson and Company, AstraZeneca, Viatris Inc. (Mylan N.V.)

Developments:

•  In 2024, Partnered with Grand River Aseptic Manufacturing to provide fill-finish services for the Maggie 5.0® autoinjector, enhancing drug delivery solutions. 
•  In 2024, Wainua was launched in the U.S., offering a self-administered option for treating hereditary transthyretin-mediated amyloidosis.
•  In 2023, Introduced the Elexy, a reusable electromechanical autoinjector, reflecting SHL's commitment to sustainability in drug delivery solutions.

For more Lifesciences and Healthcare Market reports - Please click here